Our CEO, Florence Séjourné will be attending JPM 2018 in January and we are looking forward to sharing all the recent news about DAV132 development that you may have seen in the press recently. We welcome partnering requests to discuss out-licensing or collaborations for our most advanced asset, DAV132. To request a meeting please visit the BioPartnering Platform or email us at: email@example.com
In order to prevent devastating Clostridium difficile infections and combat antibiotic resistance, Da Volterra is advancing clinical development for DAV132 which aims to prevent CDIs by protection of the intestinal microbiota. DAV132 has demonstrated excellent safety in four Phase 1 clinical trials and is entering Phase 2 in early 2018. To learn more about DAV132 please follow the link.